RESUMO
Autophagy and apoptosis have been regarded as important processes in the development of diabetic erectile dysfunction (DMED). Probucol is considered to have anti-apoptotic effects, but its relationship with autophagy has not been reported. The aim of this study was to investigate the effects and mechanisms of probucol on erectile function. Thirty Sprague-Dawley (SD) male rats (12 weeks old) were fasted for 12 h. Twenty SD rats were injected with a single intraperitoneal injection of 60 mg kg-1 streptozotocin (STZ). Ten rats were given vehicle only and used as a sham group. After 72 h, 20 STZ-treated rats with random blood glucose concentrations consistently greater than 16.7 mmol l-1 were used as successfully established diabetic rats. The diabetic rats were divided randomly into two groups and treated with a daily gavage of probucol at a dose of 0 or 500 mg kg-1 for 12 weeks. After treatment, the intracavernous pressure (ICP) was used to measure erectile function upon electrical stimulation of the cavernous nerve. After euthanasia, penile tissue was examined using immunohistochemistry and Western blot to assess the protein levels of B-cell lymphoma-2 (Bcl-2), BCL2-associated X (Bax), microtubule-associated protein light chain 3-II (LC3-II), mammalian target of rapamycin (mTOR), and sequestosome 1 (P62). Caspase-3 activity was measured to determine apoptosis using a caspase-3 assay kit. After 12 weeks of treatment, the erectile function of the probucol group was significantly better than that of the DM group (P < 0.05). Bax and LC3-II protein expression and caspase-3 activity were significantly lower in the probucol group than those in the DM group (all P < 0.05), while Bcl-2, mTOR, and P62 protein expression levels were significantly higher than those in the DM group (all P < 0.05). We demonstrated that probucol inhibited apoptosis and autophagy in STZ-induced diabetic rats.
RESUMO
Objective To observe the expression ofprobucol on high glucose-induced specificity protein 1 (SP 1),kelchlike ECH associated protein 1 (Keap 1),NF-E2-related factor 2 (Nrf2) and glutamatecysteine ligase catalytic (GCLC) in the cultured human müller cells and preliminary study the antioxidation of the probucol on müller cells.Methods Primary cultured human müller cells were randomly divided into four groups:normoglycaemia group (5.5 mmol/L glucose),normoglycaemia with probucol group (5.5 mmol/L glucose+100 μmol/L probucol),hyperglycemia group (25.0 mmol/L glucose),hyperglycemia with probucol group (25.0 mmol/L glucose + 100 μmol/L probucol).Immunofluorescence staining was used to assess distribution of SP1,Keapl,Nrf2,GCLC in human Müller cells.SP1,Keapl,Nrf2 and GCLC messenger RNA (mRNA) expression was evaluated by quantitative real-time RT-PCR (qRT-PCR).Independent sample t test was used to compare the data between the two groups.Results All müller cells expressed glutamine synthetase (＞ 95％),which confirmed the cultured cells in vitro were the purification of generations of müller cells.The expressions of SP 1,Keap 1,Nrf2,and GCLC protein were positive in human müller cells.qRT-PCR indicated that SP1 (t=28.30,P＜0.000),Keap1 (t=5.369,P=0.006),and Nrf2 (t=10.59,P=0.001) mRNA in the hyperglycemia group increased obviously compared with the normoglycaemia group;GCLC (t=4.633,P=0.010)mRNA in the hyperglycemia group decreased significantly compared with the normoglycaemia group.However,SP1 (t=12.60,P=0.000) and Keapl (t=4.076,P=0.015) in the hyperglycemia with probucol group decreased significantly compared with the hyperglycemia group;Nrf2 (t=12.90,P=0.000) and GCLC (t=l 5.96,P＜0.000)mRNA in the hyperglycemia with probucol group increased obviously compared with with the hyperglycemia group.Conclusion Probucol plays an antioxidant role by inhibiting the expression of SP 1,Keap 1 and upregulating the expression of Nrf2,GCLC in müller cells induced by high glucose.
RESUMO
To explore therapeutic effect of probucol on patients with cerebral infarction (CI) complicated lower extremity atherosclerosis (LEA) and its influence on homocysteine (Hcy) level.Methods : A total of 98 CI +LEA patients treated in our hospital were randomly divided into atorvastatin group (n＝48) and probucol group (n＝50) , After one year , levels of blood lipids , inflammatory factors and Hcy , score of United States National Institu‐tes of Health Stroke Score (NIHSS) , LEA‐related indexes before and after treatment , and incidence of adverse re‐actions were compared between two groups .Results : Compared with before treatment , after one‐year treatment , there were significant reductions in levels of blood lipids (except significant rise in HDL‐C) , inflammatory factors and Hcy , NIHSS score , intima‐media thickness (IMT ) and intimal plaque size of lower extremity arteries in two groups , P＝0. 001 all .Compared with atorvastatin group after treatment , there were significant reductions in levels of blood lipids (except significant rise in HDL‐C level) , C reactive protein [(11. 78 ± 3.02) mg／L vs.(8. 56 ± 2. 45) mg／L] , tumor necrosis factor α [(5.23 ± 1. 02) ng／L vs.(4.02 ± 0.75) ng／L] , central nervous system specific pro‐tein S100β [ (0. 45 ± 0.10) μg／L vs.(0.34 ± 0. 09) μg／L] , Hcy [ (16.58 ± 4. 19) μmol／L vs.(13.25 ± 2.87) μmol／L] , NIHSS score [ (8.99 ± 1. 35) scores vs .(7.12 ± 1. 24) scores] , IMT [ (1. 50 ± 0.28) mm vs.(1.23 ± 0.24) mm] and intimal plaque size [ (1. 35 ± 0. 22 ) cm2 vs.(0. 98 ± 0. 21) cm2 ] of lower extremity arteries in probucol group , P＝0.001 all.Incidence of adverse reactions within one year in probucol group was significantly lower than that of atorvastatin group (10. 00% vs.27. 08%, P＝0.029).Conclusion : Compared with atorvastatin , Probucol can more significantly reduce levels of blood lipids , inflammatory factors and Hcy , improve lower extremity ather‐osclerosis and neurological function injury in patients with cerebral infarction complicated lower extremity athero‐sclerosis , and it＇s safe and effective .
RESUMO
Objective :To analyze influence of probucol combined atorvastatin on hemodynamics and blood lipids in patients with large artery cerebral infarction (LACI).Methods :A total of 92 LACI patients were randomly and e-qually divided into atorvastatin group and combined treatment group (received atorvastatin combined probucol ) , both groups were treated for six months .Therapeutic effect etc indexes before and after treatment were compared between two groups .Results :Compared with atorvastatin group after six-month treatment ,there were significant reductions in levels of TC [ (4.57 ± 0.82) mmol/L vs.(3.23 ± 0.71) mmol/L] ,TG [ (1.37 ± 0.45) mmol/L vs. (1.02 ± 0.34) mmol/L] ,LDL-C [ (2.52 ± 0.83) mmol/L vs .(1.50 ± 0.54) mmol/L] ,oxidized low density lipo-protein [ox-LDL ,(78.36 ± 14.05) mg/L vs.(58.37 ± 12.00) mg/L] ,left and right middle cerebral artery pulsatili-ty index (PI) [left :(0.84 ± 0.25) vs.(0.74 ± 0.14) ,right :(0.84 ± 0.23) vs.(0.74 ± 0.16)] and inflammatory factors ,and significant rise in total effective rate (69.57% vs.89.13% P＝0.020) ,left and right middle cerebral systolic blood flow velocity (Vs) [left :(87.45 ± 15.58) cm/s vs.(95.48 ± 18.34) cm/s ,right :(89.27 ± 14.36) cm/s vs.(96.18 ± 14.03) cm/s] and mean blood flow velocity (Vm) [left :(60.90 ± 16.19) cm/s vs .(76.19 ± 17.40) cm/s ,right :(62.08 ± 17.23) cm/s vs .(91.38 ± 19.26) cm/s] in combined treatment group ,P＜0.05 or ＜0.01. There was no significant difference in drug adverse reactions incidence rate between two groups , P＝1. 000 .Conclu-sion :Therapeutic effect of probucol combined atorvastatin is significantly better than that of pure atorvastatin on large artery cerebral infarction .It can more significantly improve blood lipids and intracranial artery hemodynamics with anti-inflammatory effects .
RESUMO
OBJECTIVE:To investigate the clinical efficacy and safety of atorvastatin calcium combined with probucol in the treatment of atherosclerosis. METHODS:A total of 80 patients with atherosclerosis selected from the Affiliated Hospital of Sichuan College of TCM during Jan. 2015-Jan. 2016 were randomly divided into control group and observation group according to random number table,with 40 cases in each group. Control group was given Probucol tablet 0.5 g,every 2 days. Observation group was ad-ditionally given Atorvastatin calcium tablet 20 mg,qd,on the basis of control group. Both groups were treated for consecutive 24 weeks. The levels of blood lipid,arterial plaque size and thickness before and after treatment,life quality score before treatment and 3 months after treatment were observed in 2 groups;and the occurrence of ADR was recorded. RESULTS:Before treatment, there was no statistical significance in blood lipid,arterial plaque size and thickness or life quality score between 2 groups(P>0.05). After treatment,the levels of TC,TG and LDL-C,arterial plaque size and thickness in 2 groups were decreased significant-ly,while HDL-C level and life quality score were increased significantly;the improvement of above indexes in observation group was significantly better than control group,with statistical significance(P0.05). CONCLUSIONS:Atorvastatin calci-um combined with probucol in the treatment of atherosclerosis can reduce blood lipid level and get thrombolysis,and contribute to the recovery of living ability with good safety.
RESUMO
Objective To analyze the clinical effect of probucol in prevention of contrast induced nephropathy(CIN) after percutaneous coronary intervention(PCI).Methods 96 patients with coronary heart disease requiring PCI surgery in our hospital were selected as the research subjects, and they were randomly divided into control group(48 cases) and observation group(48 cases).Both two groups were given traditional treatment, besides this, the observation group was given additional probucol (3 d treatment before and after operation,0.5 g/time,2 times/d).The renal function indicators such as serum creatinine (Scr), cystatin C(CysC), blood urea nitrogen(Bun), estimated glomerular filtration rate(eGFR), and the expression levels of C-reactive protein(CRP),interleukin-6(IL-6) and malondialdehyde(MAD) in the two groups 24 h,48 h, 72 h before and after PCI were observed and compared.And the adverse reactions during operation in the two groups were also recorded and compared.Results There were no significant differences in Scr,CysC,Bun and eGFR between the two groups before opertion(t=0.149,P=0.882;t=1.75,P=0.243;t=0.019,P=0.985).12 h after operation, the Scr,CysC,Bun and eGFR levels in the two groups were gradually increased,48 h post-treatment, the levels reached to the peak and showed a downward trend 72 h after operation;compared with the control group, the rise and decline in the observation group were more greater, and the differences were statistically significant (t=3.242,P=0.002;t=9.532,P<0.001;t=9.073,P<0.001;t=2.896,P<0.001).There were no significant differences in CRP,IL-6 and MAD between the two groups before operation (t=0.321,P=0.749;t=0.014,P=0.989;t=0.188,P=0.850).24 h after operation, the CRP,IL-6 and MAD levels in the two groups were gradually increased,48 h post treatment, the levels reached to the peak and showed a downward trend 72 h after operation;compared with the control group, the rise and decline in the observation group were more greater, and the differences were statistically significant (t=8.495,P=0.002;t=7.532,P<0.00;t=16.216,P<0.001).There were no obvious adverse reactions during operation in the two groups.Conclusion Probucol not only has lipid-regulating and atherosclerotic effects on patients with coronary heart disease, but also has certain preventive and clinical effects to CIN after PCI.Thus, it can be considered as a preferred drug for clinical prevention and treatment of CIN.
RESUMO
Objective To explore the effect of probucol on the inflammatory response in rabbits with arteriosclerosis obliterans.Methods SPF male new zealand white rabbits were subjected to incomplete right femoral artery ligation model of arteriosclerosis obliterans.The model rabbits were divided into experimental group and control group.The rabbits in experimental group were treated by probucol.After treatment for 4 weeks,HE staining was used to evaluate the injury severity of right femoral artery in rabbits;ELISA was used to measure the levels of IL-1,IL-6,TNF-α and CRP;Realtime PCR was used to detect the expressions of IL-1,TNF-α in right femoral artery;Western blot was used to measured the nucleus accumulations of NF-κB,and the phosphorylation of IκB.Results Compared with control group,the degree of pathological injury of right femoral artery was significantly atteunated,the levels of IL-1 、IL-6 、TNF-α and CRP in plasma,the mRNA expressions of IL-1 、TNF-α and the nucleus accumulations of NF-κB,and the phosphorylation of IκB in right femoral artery decreased significantly.Conclusion Probucol attenuates the inflammatory response in rabbits with arteriosclerosis obliterans significantly.
RESUMO
Objective To evaluate the effects of probucol combined with atorvastatin medication on blood levels of oxidized low-density lipoprotein (ox-LDL), lipoprotein-associated phospholipase A2 (Lp-PLA2), and the correlation of their changes in patients with acute coronary syndrome (ACS) undergoing percutaneous poronary intervention (PCI). Methods A total of 97 patients with ACS and undergoing PCI were randomly divided into two groups according to the date of admission:single medication group (n=42),the patients were taken atorvastatin 20 mg/d; and combined medication group (n=55),the patients were taken atorvastatin 20 mg/d with probucol 500 mg/d. The plasma levels of ox-LDL and Lp-PLA2 were measured in both groups before and 6-8 weeks after the medication. Then the results were compared and analyzed between two groups. Results (1) Before treatment there were no significant differences in levels of ox-LDL and Lp-PLA2 between two groups (P>0.05). After the treatment, the ox-LDL level was significantly decreased in combined medication group (P<0.01). After the treatment, the levels of Lp-PLA2 were significantly decreased than those before treatment in both groups (P<0.01). Compared with single medication group, levels of ox-LDL and Lp-PLA2 were significantly lower in combined medication group (P < 0.01). (2) After treatment, the absolute value of Lp-PLA2 decline (ΔLp-PLA2) was positively correlated with the absolute value of ox-LDL decline (Δox-LDL) in combined medication group (r=0.314, P=0.020). Conclusion Probucol combined with statin therapy can reduce ox-LDL and Lp-PLA2 levels, and with a positive correlation between them. Probucol can further decrease the level of Lp-PLA2 by inhibiting ox-LDL production, which may be one of the mechanisms of its anti-atherosclerosis.
RESUMO
Objective The aim of the study was to investigate the protective effect of probucol on oxidative stress injury in rats with ischemia-reperfusion injury(IRI)and its mechanism. Methods Thirty male Sprague-Dawley rats were randomly di-vided into sham operation group(S group),ischemia-reperfusion group(IR group),and probucol treatment group(probucol+IR group,P+IR group).Rats in the S and IR groups were fed with warm water every day,and rats in P+IR group were treated with probucol.After 1 week,rat model of renal ischemia and reperfusion was established.Right kidneys of the rats were re-moved.In IR and P+ IR groups,the left renal artery was clamped with a non-invasive artery clamp,and after 30 minutes the blood vessels restored patency by loosening the clamp.After reperfusion,the S and IR groups were perfused with warm water every day,and the P+IR group was treated with probucol for 1 week.After 1 week,all the rats were sacrificed and the blood and kidney tissue specimens were taken.The blood biochemical indexes of the rats were measured,and the pathological changes of the kidneys were observed.Results The levels of blood urea nitrogen(BUN),serum creatinine(SCr)and blood lipids in P+ IR group were significantly lower than those in IR group(all P<0.05);in P+IR group,the level of superoxide dismutase(SOD)in serum and renal tissue was increased significantly(all P<0.05),meanwhile,the levels of malondialdehyde(MDA)were significantly decreased (P<0.05).In P+IR group,the pathological damage of kidney tissue was reduced,and renal index was significantly improved(P<0.05).Conclusion Probucol can increase the activity of SOD in blood and kidney of rats with IRI,improve renal function,reduce the level of blood lipids,reduce the pathological injury of renal tissue,and play a role in renal protection.
RESUMO
OBJECTIVE:To explore the effectiveness and safety of probucol combined with rosuvastatin in the treatment of vascu-lar dementia(VD). METHODS:In retrospective study,clinical information of 88 VD patients selected from neurology department of our hospital during May 2013-Feb. 2015 were divided into observation group and control group according to therapy plan,with 44 cas-es in each group. Both groups received conventional treatments such as controlling blood pressure and blood glucose,anticoagulation. Control group was additionally given Rosuvastatin calcium tablets orally 20 mg,at bedtime;observation group was additionally given Probucol tablet 0.5 g,bid,after meal,on the basis of control group. Both groups received treatment for consecutive 3 months. MMSE and ADL score were compared between 2 groups before and after treatment as well as the levels of TC,TG,LDL-C,HDL-C,CRP, TNF-α,IL-6,IL-1β,SOD and MDA. The occurrence of ADR was also observed. RESULTS:Before treatment,there was no statisti-cal significance in above indexes between 2 groups(P>0.05). Compared to before treatment,MMSE and ALD score,serum SOD lev-el of 2 groups were increased significantly,while serum levels of TC,TG,LDL-C,CRP,TNF-α,IL-6,IL-1βand MDA were de-creased significantly after treatment,with statistical significance(P0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05).CONCLUSIONS:Probucol combined with rosuvastatin is better than rosuvastatin alone in reducing blood lipid,serum inflamma-tory factors and oxidant stress indexes levels,improving cognitive function and quality of life with good safety.
RESUMO
Objective:To explore influence of probucol combined atorvastatin on blood viscosity ,transcranial Doppler (TCD) indexes and carotid plaque stability in patients with large artery‐derived cerebral infarction .Methods :A total of 100 patients with large artery‐derived cerebral infarction treated in our hospital from Apr 2014 to Apr 2016 were selected .According to random number table ,patients were randomly and equally divided into atorvastatin group (received atorvastatin based on routine treatment ) and combined treatment group (received probucol based on atorv‐astatin group) ,both groups were treated for six months .Related indexes before and after treatment were compared between two groups .Results :Compared with atorvastatin group after treatment ,there were significant reductions in levels of TC ,TG and LDL‐C ,and significant rise in HDL‐C level (P<0.01 all);significant reductions in whole blood high shear viscosity [(6.23 ± 0.38) mPa/s vs .(4.20 ± 0.42) mPa/s] ,whole blood low shear viscosity [(21.17 ± 5.83) mPa/s vs .(18.10 ± 4.44) mPa/s] ,plasma viscosity [ (2.10 ± 0.45) mPa/s vs .(1.72 ± 0.34) mPa/s] and fibrinogen (Fg) level [(4.35 ± 1.36) g/L vs .(3.30 ± 1.38) g/L] ,P<0.01 all;significant rise in systolic blood flow velocity (Vs) [left :(87.43 ± 14.56) cm/s vs .(95.45 ± 18.37) cm/s]and mean blood flow velocity (Vm) [left :(60.89 ± 16.03) cm/s vs .(75.38 ± 19.36) cm/s]of left and right MCA ,significant reduction in pulsatility index(PI) [(0.85 ± 0.22) vs .(0.75 ± 0.12)] , P<0.05 or <0.01;significant reductions in unstable plaque score [(4.93 ± 0.40) scores vs .(4.12 ± 0.35) scores]and recurrence rate of cerebral infarction (16.00% vs .2.00% ) in combined treatment group ,respectiely P=0.001 ,0.014. Conclusion:Probucol combined atorvastatin can significantly reduce blood viscosity ,significantly improve hemodynamics in patients with large artery‐derived cerebral infarction .Its an‐ti‐atherosclerosis effect is obvious ,therefore it can be used to prevent or reduce recurrence of cerebral infarction .
RESUMO
Objective:To explore the clinical efficacy, especially the comprehensive improvement of blood glucose and lipid of probucol and metformin in the treatment of type 2 diabetes mellitus with hyperlipidemia. Methods:Totally 105 patients with type 2 di-abetes mellitus complicated with hyperlipidemia were randomly divided into the control group1 (35 cases), the control group 2 (34 ca-ses) and the observation group (36 cases). The control group 1 was treated with diet control, exercise and metformin, the control group 2 was treated with rosuvastatin calclum tablets based on the group 1, and the observation group was treated with probucol based on the group 1. The three groups were continuously treated for 12 weeks. The improvement of the fasting blood-glucose (FPG), 2h postprandial blood glucose (PBG), hemoglobin A1C (HbA1C), fasting insulin levels (Fins), insulin resistance indices (HOMA-IR) and TC, TG and HDL-C, and the adverse reactions among the three groups were compared. Results:The total effective rate in the ob-servation group was higher than that in the control group 1 and 2 (P0. 05). Conclusion:Probucol as one of lipid-lowing drugs with antioxidant action combined with metformin can improve blood lipid and lower blood glucose at the same time, which is worthy of promoted application in clinics.
RESUMO
OBJECTIVE:To explore the effects and safety of atorvastatin combined with probucol on the vascular elasticity in patienits with hypertension. METHODS:246 hypertensive patients were randomly divided into control group and observation group,123 cases in each group. All patients received conventional antigypertensive treatment,based on it,control group was given 10 mg Atorvastatin tablet,qd;observation group was additionally given 0.25 g Probucol tablet,qd,on the basis of control group. They were treated for 1 year. Clinical efficacy,lipid levels(total cholesterol,triglyceride,low density lipoprotein cholesterol,high density lipoprotein cholesterol),cystatin C (Cys-C),C-reactive protein (CRP),elastic parameters of common carotid artery and lower limb artery(stiffness,pressure-strain elastic modulus,compliance,augmentation index,pulse wave velocity)before and af-ter treatment in 2 groups were observed,and the incidence of adverse reactions was compared. RESULTS:Before treatment,there were no significant differences in lipid levels,Cys-C,CRP and elastic parameters of common carotid artery and lower between 2 groups (P>0.05);after treatment,the above-mentioned indexes were significantly improved,and the improvement degree in ob-servation group was superior to control group,the differences were statistically significant(P<0.05). And there were no severe ad-verse reactions during treatment in both 2 groups. CONCLUSIONS:Atorvastatin combined with probucol can improve lipid level and elasticity of common carotid artery and lower limb artery,with good safety.
RESUMO
OBJECTIVE:To explore the efficacy and safety of probucol combined with butylphthalide in the treatment of pa-tients with acute cerebral infarction. METHODS:172 patients with acute cerebral infarction were randomly divided into observation group and control group,86 cases in each group. All patients received conventional treatment for acute cerebral infarction,includ-ing thrombolysis,anti-platelet aggregation,reducing intracranial pressure,nutritional support,intensive lipid-lowering within onset 4.5 h,timely treatment of the underlying diseases;based on it,control group received Probucol tablet,0.5 g every times,bid. Ob-servation group additionally received Butylphthalide and sodium chloride injection,100 ml every times,bid,in 9:00 and 17:00 ev-ery day,infusion within 50-90 min. Both groups lasted for 2 weeks. Lipid metabolic indexes,the changes of serum S100β,NSE and hs-CRP levels,NIHSS score,clinical efficacy before and after treatment,and the incidence of adverse reactions in 2 groups were observed. RESULTS:Compared with before treatment,triglyceride(TG),total cholesterol(TC)and low-density lipoprotein cholesterol (LDL-C) levels in 2 groups significantly decreased,high-density lipoprotein cholesterol level significantly increased, and TG,TC and LDL-C levels in observation group decreased more significantly,the differences were statistically significant(P<0.05). Serum S100β,NSE and hs-CRP levels and NIHSS scores in 2 groups significantly decreased,and NSE level NIHSS scores and in observation group decreased more significantly,the differences were statistically significant (P<0.05). The total effective rate in observation group was 89.5%,significantly higher than control group (62.8%),the difference was statistically significant (P<0.05). There were no obvious adverse reactions during treatment,and also no obvious liver and kidney function,blood coagula-tion and ECG changes. CONCLUSIONS:Probucol combined with butylphthalide can effectively improve the lipid metabolism and decrease serum NSE level in the treatment of patients with acute cerebral infarction,and plays positive role in early recovery of neu-rological function.
RESUMO
Objective: To explore the effect of probucol on enzyme and receptors of high density lipoprotein (HDL) during reverse cholesterol transportation in experimental rabbits with atherosclerosis. Methods: A total of 24 New Zealand rabbits were randomly divided into 3 groups: Control group, the rabbits were fed by normal diet, High cholesterol group, the rabbits were fed by high cholesterol diet and Probucol group, the rabbits were fed by high cholesterol diet with probucol.n=8 in each group, all animals were treated for 12 weeks. Blood levels of lipids were examined by colorimetric method, serum lecithin cholesterol acyltransferase (LCAT) and cholesterol ester transfer protein (CETP) were detected by ELISA, expressions of ATP binding cassette transporter A1 (ABCA1) and scavenger receptor class B type I (SR-BI) in aortic plaque were measured by immunohistochemistry; the above indexes were compared among different groups. Results: ① for blood lipids by mmol/L, the following indexes in Probucol group were lower than High cholesterol group: TC (15.95±1.51 vs 21.95±3.71), LDL-C (13.01±2.28 vs 17.90±3.51), HDL-C (0.56±0.10 vs 1.13±0.12), all PConclusion: Probucol may increase blood levels of LCAT, CETP via up-regulating the expressions of ABCA1, SR-B1 and elevating the reverse cholesterol transportation of HDL, therefore improve HDL function in experimental rabbits with atherosclerosis.
RESUMO
Objective:To analyze the effect of rosuvastatin combination probucol on patients with carotid atherosclerotic plaque.Methods:Chosen patients with carotid atherosclerotic plaque in our hospital as research subjects, randomly assigned to control group received probucol alone and observation group received rosuvastatin combined probucol, compared IMT and OX-LDL levels inflammatory factors levels, incidence of adverse. Results:1)Observation group patients’ IMT and ox-LDL levels after treatment were significantly lower than control group patients(t=4.327,t=5.783;P<0.05); 2)Observation group patients’ hs-CRP, IL-6 and MMP-9 levels after treatment were significantly lower than control group patients (t=6.422,t=5.184,t=5.291;P<0.05); 3)Follow-up of 5 years, observation group patients vascular occlusion, plaque off , brain stem rate were significantly lower than control group patients (x2=4.827, x2=5.894,x2=5.937;P<0.05).Conclusion: Rosuvastatin can effectively reduce joint Probucol carotid atherosclerosis intima-media thickness sclerosis patients and reduce the level of oxidized LDL, inflammatory cytokines optimization, and ultimately reduce the incidence of adverse events, with positive clinical significance.
RESUMO
To study the antioxidative stress effect of probucol for nonproliferative diabetic retinopathy. METHODS: Sixty - eight clinic patients with nonproliferative diabetic retinopathy were selected from January, 2012 to August, 2013. According to the random number table, the patients were divided into control group and observation group, the control group was received conventional medicine for hypoglycemic therapy, and the observation group was given probucol (0. 375g, twice daily) on the basis of control group. All patients were followed up for average 11. 58 ± 0. 17mo. At the same time 16 healthy volunteers matched with baseline were collected as normal control group. Changes in fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, the staging progress rate and the remission rate of diabetic retinopathy, and indicators related to oxidative stress, such as, total antioxide capacity ( TAOC ) , superoxide dismutase ( SOD ) , and methane dicarboxy aldehyde ( MDA ) , of two groups of patients before and after therapy were observed.RESULTS: Fasting blood glucose, postprandial blood glucose, and glycosylated hemoglobin of patients in two groups before and after therapy showed no significant changes, and the differences had no statistical significance. The staging remission rate and the progress rate of diabetic retinopathy of the control group after therapy were 3% and 19% respectively. The staging remission rate and the progress rate of diabetic retinopathy of the observation group after probucol therapy were 18% and 5% respectively. ln comparison with the control group, the difference had statistical significance (P<0. 05). TAOC, SOD, MDA of the control group before and after therapy had no obvious change, but TAOC, SOD of the observation group after therapy had significantly increased, and MDA had significantly decreased ( P < 0. 05 ), with statistical significance in comparison with the changes of the patients in the control group after therapy (P<0. 05).CONCLUSlON:Probucol can improve the antioxidative stress status of the patients with nonproliferative diabetic retinopathy, and enhance the therapeutic effect of the patients with diabetic retinopathy.
RESUMO
OBJECTIVE:To observe short-term efficacy and safety of early use of tirofiban combined with different lipid-regu-lating drugs percutaneous coronary intervention(PCI)in elderly patients with coronary heart disease. METHODS:562 elderly pa-tients with coronary heart disease underwent selective PCI were selected and randomly divided into atorvastatin group and probucol group,with 281 cases in each group. Both group received routine treatment;atorvastatin group was additionally given tirofiban combined with Atorvastatin tablet,and probucol group was additionally given irofiban combined with Probucol tablet. Clinical indi-cators and main adverse cardiac event(MACE)were compared between 2 groups before and after treatment. RESULTS:After treat-ment,3 level of thrombolysis in myocardial infarction(TIMI)in atorvastatin group accounted for 69.4%,which was significantly lower than 95.7% of probucol group,with statistical significance(P0.05). CONCLUSIONS:Tirofiban combined with different lipid-regulating drugs can effectively improve the prognosis of elderly patients with coronary heart disease after PCI operation with good safety,but tirofiban combined with pro-bucol has more obvious therapeutic effect.
RESUMO
Objective To explore the influence of the combination therapy of probucol with atorvastatin on levels of serum high sensitivity C-reactive protein (hs-CRP), oxidized low-density lipoproteins (ox-LDL), and marix metallopro? teinase-9 (MMP-9) and resolution of carotid plaque in patients with acute cerebral infarction (ACI). Methods One hun? dred-six patients with acute cerebral infarction who had carotid artery color Doppler ultrasound-confirmed atherosclerot? ic plaques , were included in the present study. The patients were randomly divided into two groups: conventional treat? ment group ( 40 cases) which received atorvastatin (20mg/d) and co-treatment group (40 cases) which received Atorvas? tatin (20mg/d) and Probucol (500mg/d). Levels of hs-CRP, ox-LDL and MMP-9 were detected in all patients before treat? ment and 1, 6 and 12 months after drug therapy. The Intima-media thickness, area and numbers of carotid plaques were evaluated by using Doppler ultrasonography during a 12 months follow-up period. Results ① Serum hs-CRP and MMP-9 levels were significantly decreased at 1, 6 and 12 months after treatment, (conventional treatment group:t =14.662, 23.586, 28.179 and co-treatment group:t =47.023, 50.239, 50.774,P 0.05) at 1, 6 and 12 months after treatment. Serum hs-CRP, ox-LDL and MMP-9 levels were significantly lower in com? bined treatment group than in the conventional treatment group at all time points after treatment (t =7.655, 5.271, 2.492, t =4.927, 3.772, 4.673 andt =16.862, 4.251, 2.045.P 0.05). The IMT, plaque area and plaque numbers were significantly smaller in combined treatment group than in conventional treatment group (t =6.117, 3.290, 2.158,P <0.05). Conclusions The combination therapy of probucol with atorvastatin can greatly reduce levels of serunl hs-CRP,ox-LDL and MMP-9, indicating that the combination therapy has a strong anti-oxidant function, thereby reversing and stabilizing the atherosclerosis plaque.
RESUMO
Objective To measure the renal cortex blood flow leVel in Patients with stage 3-4 chronic kidney disease, and to obserVe the effect of Probucol on renal cortex blood flow and renal function. Methods Twenty Patients with stage 3-4 chronic kidney disease in our hosPital were randomly diVided into treatment grouP ( 10 Patients ) and obserVation grouP ( 10 Patients). Ten healthy subjects were chosen as the control grouP. Dynamic sonograPhic tissue Perfusion measurement (DTPM) was used to eValuate the mean flow intensity (Imix),mean flow Velocity (Vmix) and tissue resistance index (TRI) in the three grouPs. Patients in the obserVation grouP were treated with standard theraPy;the treatment grouP was giVen Probucol 500 mg,twice daily in addition to standard theraPy for 6 months. The renal cortex blood flow leVel after treatment was measured in the treatment grouP and obserVation grouP. The serum BUN,SCr,TC,TG,LDL,HDL,hs_CRP,ox_LDL,PA,ALB before and after treatment were measured and comPared between the treatment grouP and obserVation grouP. Results Imix and Vmix were significantly lower,and TRI was significantly higher in the treatment grouP and obserVation grouP than in the control grouP (P<0. 01). After 6 months of treatment,Imix and Vmix in the treatment grouP were significantly increased and TRI significantly decreased as comPared with the baseline and the control grouP (P<0. 01). After treatment,Imix and Vmix were significantly decreased and TRI was significantly increased in the obserVation grouP (P<0. 05). In the treatment grouP,the serum BUN,SCr,TC,TG,LDL,hs_CRP and ox_LDL decreased and PA,ALB and HDL increased after treatment as comPared with the baseline and the obserVation grouP (P<0. 05 or P<0. 01). Conclusion The renal cortex blood flow leVel is significantly lower in Patients with stage 3-4 chronic kidney disease than in the healthy PeoPle. Probucol can imProVe the renal cortex blood flow leVel significantly,Protect the renal function, and imProVe microinflammatory state,nutrition status and dysliPidemia.